Notes: Aug. 9, 2016 -- ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to purchase up to 35,250,000 shares of its common stock at a public offering price of $0.16 per share and related base warrant, for total expected gross proceeds to ImmunoCellular of approximately $7.4 million, before deducting underwriting discounts, commissions, and other offering expenses. The base warrants have an exercise price of $0.1921 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. ImmunoCellular has applied to list the base warrants on the NYSE MKT and expects trading to begin following their issuance at closing under the ticker symbol IMUCWS. The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions.